7 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 humanized monoclonal anti-FGFR1 antibody OM-RCA-01 - Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Kidney Cancer Research Bureau | 64 | 2025-12-02 | 2026-11-10 |
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles - Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 | Active not recruiting | Tyra Biosciences, Inc | 40 | 2023-11-22 | 2026-10-14 |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-11-03 |
| Phase I BLASST-3 Trial Infigratinib - Bladder Transitional Cell Carcinoma, Bladder Cancer | Phase 1 | Withdrawn | Guru P. Sonpavde | 2021-12-23 | 2022-08-10 | |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 51 | 2020-10-09 | 2026-07-17 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) Pemigatinib - Solid Tumors | Phase 1 | Completed | Incyte Corporation | 44 | 2017-08-01 | 2020-05-29 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies INCB062079 - Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | Phase 1 | Terminated | Incyte Corporation | 25 | 2017-05-25 | 2025-10-21 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors BGJ398, BYL719 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 62 | 2013-10-01 | 2020-12-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3 - Tumor or Lymphoma | Phase 1 | Completed | Janssen Research & Development, LLC | 188 | 2012-06-15 | 2025-02-03 |
| Amicar Pharmacokinetics of Children Having Craniofacial Surgery Epsilon-Aminocaproic Acid - Craniosynostosis | Phase 1 | Completed | Paul Stricker | 18 | 2009-05-01 | 2012-11-01 |
Acrocephalosyndactylia (11) · Breast Neoplasms (3) · Urinary Bladder Neoplasms (3) · Cholangiocarcinoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1)
Bone Diseases (12) · Bone Diseases, Developmental (12) · Congenital Abnormalities (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Craniofacial Abnormalities (12) · Dysostoses (12) · Musculoskeletal Abnormalities (12) · Musculoskeletal Diseases (12) · Synostosis (12) · Limb Deformities, Congenital (11) · Syndactyly (11) · Neoplasms (9) · Neoplasms by Site (9) · Female Urogenital Diseases (5)
derazantinib (2) · infigratinib (2) · Alpelisib (1) · Aminocaproic Acid (1) · Fulvestrant (1) · atezolizumab (1) · erdafitinib (1) · exemestane (1) · pemigatinib (1)
Basilea Pharmaceutica (2) · Incyte Corporation (2) · Eisai Co., Ltd. (1) · Guru P. Sonpavde (1) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · Kidney Cancer Research Bureau (1) · Novartis Pharmaceuticals (1) · Paul Stricker (1) · Tyra Biosciences, Inc (1)
United States (7) · France (4) · Spain (4) · Australia (3) · Belgium (3) · Germany (3) · Italy (3) · Japan (3) · South Korea (3) · Canada (2) · Poland (2) · Russia (2) · Switzerland (2) · United Kingdom (2) · Argentina (1)
Doug Warner (1) · Ekaterine Asatiani, MD (1) · Guru Sonpavde, MD (1) · Luis F. Vinas, MD (1) · Paul Stricker, MD (1)
PMID 26324363, PMID 31088831, PMID 31280362, PMID 36787089, PMID 38627238
2017 (1), 2019 (1)